ImmunityBio

Historical price data

ImmunityBio is a clinical-stage biotech focused on developing a 'Cancer BioShield' through its proprietary immunotherapy platforms, including the IL-15 superagonist ANKTIVA® and off-the-shelf NK cell therapies. The company's core mission is to defeat cancer and infectious diseases by enhancing, rather than weakening, the patient's immune system. Its first FDA approval in 2024 for bladder cancer validates its scientific approach and provides a commercial foundation for expanding into multiple solid tumor and infectious disease indications.

Integrated 'triangle offense' immunotherapy platform featuring the first-in-class IL-15 superagonist ANKTIVA® to stimulate NK and T cells, combined with off-the-shelf activated NK (aNK) cell therapies and next-generation adenoviral cancer vaccines.

Faces competition in IL-15 space from several clinical-stage biotechs, in bladder cancer from checkpoint inhibitors and gene therapies, and in NK cell therapy from multiple allogeneic platforms. Its differentiated 'triangle offense' strategy aims to synergize with, rather than directly replace, existing modalities.